Start Sub Navigation

Start Global Navigation

  1. About RCAST
  2. Research
  3. Activities
  4. Industry-Academia-Government Collaboration
  5. International Collaboration
  6. Education
Research

Start Main Contents

RCAST NEWS

Clinical Epigenetics funded research division holds inaugural lectures [ 2012/11/08 ]

Inaugural lectures were held on November 8 by Clinical Epigenetics, the new research division headed by Project Professor Toshiro FUJITA.

Belonging to the field of life sciences, one of RCAST's current core areas, the division was established this year through donations by ten companies.

At the opening event, RCAST Director Yoshiaki NAKANO stated, ""This division was inaugurated with the goal of understanding the pathophysiology of salt sensitive hypertension and chronic renal disease from the perspective of epigenetics, and of developing diagnostic and treatment applications."" NAKANO also expressed the ""hope that today's kick-off will lead to further advanced research."" Professor Tatsuhiko KODAMA of the Laboratory for System Biology and Medicine gave the congratulatory address at the well-attended event.

Director Yoshiaki NAKANO greets the crowd at the opening ceremony
Director Yoshiaki NAKANO greets the crowd at the opening ceremony
Professor Tatsuhiko KODAMA gives the congratulatory address for the establishment of the new research division
Professor Tatsuhiko KODAMA gives the congratulatory address for the establishment of the new research division
Professor Toshiro FUJITA, head of the Clinical Epigenetics Research Division
Professor Toshiro FUJITA, head of the Clinical Epigenetics Research Division

 Professor Hiroyuki ABURATANI offers the toast at the inauguration party
Professor Hiroyuki ABURATANI offers the toast at the inauguration party



Companies participating in the Clinical Epigenetics funded research division
(In random order) MSD K.K., Omron Healthcare Co., Ltd., Kyowa-Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co., Ltd., Toray Industries, Inc., Boehringer Ingelheim Pharma GmbH & Co., Mochida Pharmaceutical Co., Ltd., Astellas Pharma Inc., Fukuda Denshi

Start Site Information

page top